Henry Schein (NASDAQ:HSIC) Given New $87.00 Price Target at UBS Group

Henry Schein (NASDAQ:HSIC) had its price objective raised by UBS Group from $79.00 to $87.00 in a research note released on Wednesday morning,Benzinga reports. They currently have a neutral rating on the stock.

HSIC has been the topic of several other research reports. JPMorgan Chase & Co. lifted their target price on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday. Wells Fargo & Company boosted their target price on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday. Leerink Partners raised their target price on shares of Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research note on Tuesday. Robert W. Baird set a $100.00 price objective on Henry Schein and gave the company an “outperform” rating in a research report on Monday. Finally, Mizuho boosted their target price on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $85.58.

Henry Schein Stock Down 1.8%

HSIC opened at $81.87 on Wednesday. The stock has a market cap of $9.64 billion, a price-to-earnings ratio of 25.04, a price-to-earnings-growth ratio of 2.48 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.79 and a current ratio of 1.38. The firm’s fifty day moving average is $77.66 and its 200 day moving average is $71.97. Henry Schein has a fifty-two week low of $60.56 and a fifty-two week high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The business had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the prior year, the business posted $1.19 EPS. Henry Schein’s revenue for the quarter was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, sell-side analysts forecast that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Institutional Trading of Henry Schein

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its stake in Henry Schein by 47.3% during the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after buying an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after purchasing an additional 229 shares during the period. Acadian Asset Management LLC bought a new position in Henry Schein during the 1st quarter valued at about $676,000. Asset Management One Co. Ltd. raised its position in Henry Schein by 9.8% in the 2nd quarter. Asset Management One Co. Ltd. now owns 8,286 shares of the company’s stock worth $605,000 after purchasing an additional 739 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in Henry Schein by 24.8% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,272 shares of the company’s stock worth $458,000 after purchasing an additional 1,247 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Key Headlines Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Company beat Q4 estimates on both EPS and revenue (Q4 EPS $1.34 vs $1.30 est.; revenue $3.44B vs $3.34B) and gave FY‑2026 EPS and revenue guidance roughly in line with consensus — a core driver of the recent rally. Article Title Press Release
• Positive Sentiment: Several brokers raised price targets or upgraded the stock after the earnings beat: JPMorgan to $92 (Overweight), Robert W. Baird upgraded to Outperform with a $100 target, UBS, Mizuho, Wells Fargo and Leerink also lifted targets into the mid‑$80s–$100 range — supporting upside expectations. Benzinga roundup TickerReport
• Positive Sentiment: Market momentum: the shares recently hit a 52‑week high as investors re‑rated growth from equipment, specialty and tech segments after the call. MSN article
• Neutral Sentiment: FY‑2026 guidance was close to Street expectations (EPS 5.23–5.37 vs consensus ~5.28; revenue $13.6–13.8B vs ~$13.5B), which reduces surprise risk but doesn’t materially raise the bar for beat-and-raise momentum. Press Release
• Negative Sentiment: Margin pressures flagged on the call and in analyst notes — revenue growth was strong but margins contracted, which some analysts cite as a reason to temper enthusiasm and cap multiple expansion. Zacks margin note
• Negative Sentiment: Not all analysts turned positive — Morgan Stanley (Erin Wright) maintained a sell/underweight stance with a much lower $58–$61 price target, and some investors may have taken profits or remained cautious because of valuation vs. margin risk. TipRanks Benzinga note

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.